This was demonstrated by Cortez-Retamozo et al. in 2004 who targeted tumour cells through the nanobodies fused to the β-lactamase enzyme to identify the carcinoembryonic antigen [169]. The enzyme converts an injected non-toxic pro-drug into a toxic drug with an elevated concentration in the targeted tumour cells. Here, CEACAM5 is linked to neoplasm.